A pioglitazone and empagliflozin compound tablet and its preparation method and application

By screening excipients and optimizing process parameters, pioglitazone and empagliflozone compound tablets were prepared, which solved the problems of drug stability and slow dissolution, improved the treatment effect and patient compliance with medication, and achieved high bioavailability of the drug and stability.

CN118787603BActive Publication Date: 2024-11-19ORYZA PHARMACEUTICALS SHENZHEN LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411286754.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-13
Publication Date
2024-11-19
Estimated Expiration
2044-09-13

AI Technical Summary

Technical Problem

When there are pioglitazone combined with other drugs, there are problems such as difficult to ensure drug stability, slow dissolution, complex management and high price, which affects the treatment effect and patient compliance with medication.

Method used

By screening appropriate auxiliary materials and prescription ratios, using fluidized bed granulation process and specific process parameters, pioglitazone and empagliflozin compound tablets were prepared, oligomeric proanthocyanins were added to improve dissolution and stability, and optimizing viscosity. The ratio of mixture and disintegrant ensures rapid dissolution of drugs in the body and high bioavailability.

Benefits of technology

The high dissolution, stability and bioavailability of compound tablets are achieved, the side effects of the drug are reduced, the treatment effect and patient compliance with medication are improved, and the storage risk of drugs and microbial contamination are reduced.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118787603B_ABST
    Figure CN118787603B_ABST
Patent Text Reader

Abstract

The present invention discloses a pioglitazone and empagliflozin compound tablet and a preparation method and application thereof. The compound tablet comprises the following components in parts by weight: 24-36 parts of pioglitazone, 5-10 parts of empagliflozin, 4-6 parts of oligomeric proanthocyanidins, 146-315 parts of fillers, 10-20 parts of binders, 10-16 parts of disintegrants, 1-3 parts of lubricants, and 1-2 parts of glidants; wherein the mass ratio of the binder to the empagliflozin is (2-4): 1. The compound tablet drug of the present invention can be rapidly dissolved, and by adding various additives and oligomeric proanthocyanidins, the dissolution stability can be high at high temperature and high humidity, and the storage stability is high, and the growth of microorganisms in the preparation can be inhibited to prevent the drug from being contaminated and degraded by microorganisms.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of pharmaceutical technology, and in particular to a pioglitazone and empagliflozin compound tablet, and a preparation method and application thereof. Background Art

[0002] Pioglitazone is an oral antidiabetic drug belonging to the thiazolidinedione class. It is a highly selective peroxide proliferator-activated receptor (PPAR) agonist that controls blood sugar by increasing insulin sensitivity in the periphery and liver. Its main mechanism of action is to activate PPAR nuclear receptors in tissues such as fat, bone and liver where insulin acts, thereby regulating the transcription of insulin-responsive genes and controlling the production, transport and utilization of blood sugar. However, pioglitazone has the risk of causing or aggravating congestive heart failure. Therefore, in actual treatment, in order to reduce the risk of heart failure caused by long-term use of pioglitazone, it is necessary to consider compounding with other drugs. However, taking drugs separately requires purchasing multiple drugs separately, which is expensive. When patients manage according to the time and dosage of different drugs, confusion and errors may occur. Taking drugs multiple times may reduce patients' compliance with medication, thereby affecting the treatment effect. And when it is necessary to adjust the dosage of a drug, the influence of another drug needs to be considered separately, which increases the complexity of the drug. The stability of the compounded drug composition is difficult to guarantee. When making compound preparations, it is necessary to consider the effect of multiple active ingredients on the absorption rate and degree of a single drug in the body. If the drug dissolves too slowly in vitro, it will lead to incomplete absorption of the drug in the body, thereby affecting the efficacy of the drug after compounding. Therefore, it is necessary to ensure that the drugs in the compound preparation have a high solubility and ensure that they can achieve the same bioavailability when acting in the body. Summary of the invention

[0003] In view of the defects in the prior art, the present invention provides a pioglitazone and empagliflozin compound tablet and its preparation method and application. The present invention selects suitable auxiliary materials, prescription ratios and preparation methods to make the obtained compound tablets have good formability, high dissolution performance and good tablet stability.

[0004] The invention discloses a pioglitazone and empagliflozin compound tablet, which comprises the following components in parts by weight: 24-36 parts of pioglitazone, 5-10 parts of empagliflozin, 4-6 parts of oligomeric proanthocyanidins, 146-315 parts of fillers, 10-20 parts of binders, 10-16 parts of disintegrants, 1-3 parts of lubricants, and 1-2 parts of glidants; wherein the mass ratio of the binder to the empagliflozin is (2-4):1, preferably 2:1.

[0005] Through experimental research, the present invention found that under specific concentrations and process conditions, the dissolution rate of empagliflozin can be significantly improved. When the binder and empagliflozin are compounded in a ratio of 2:1, by controlling the process parameters of fluidized bed granulation, controlling the air volume and air temperature, and controlling the material temperature, the above mixture is sprayed onto the surface of the material by atomization, and empagliflozin particles with good fluidity and fast dissolution rate can be prepared. Further increasing the ratio of the binder to 4:1, the prepared empagliflozin particles still show an excellent dissolution rate. However, further increasing the application ratio of the binder, due to the high viscosity of the binder, causes the prepared particles to easily agglomerate, which in turn reduces the dissolution rate of empagliflozin.

[0006] Among them, the molecular structure of oligomeric proanthocyanidins (OPC) is as follows:

[0007] ;

[0008] Among them, n=2~4.

[0009] The present invention screens the components of the compound preparation and finds that adding a certain amount of oligomeric proanthocyanidins to the pioglitazone and empagliflozin compound tablets further improves the solubility of pioglitazone and empagliflozin in the compound preparation and the stability of the compound preparation, thereby improving the stability and absorption rate of the drugs in the body and ensuring the effectiveness of the combined medication.

[0010] Furthermore, the D50 particle size of the pioglitazone is 20-40 μm; the D50 particle size of the empagliflozin is 5-15 μm. The present invention finds that the particle size of the drug can affect the dissolution and stability of pioglitazone and empagliflozin when compounded. By optimizing the particle sizes of the two, the dissolution stability of the drug in the compound tablet is ensured to be high and not easily affected by temperature and humidity.

[0011] Furthermore, the filler is any one of microcrystalline cellulose, lactose, and pregelatinized starch.

[0012] Further, the binder is any one of hydroxypropyl methylcellulose and povidone. The present invention regulates the amount of binder added to avoid excessive binder causing a decrease in drug solubility. The binder is preferably povidone, which has a good solubilizing effect on pioglitazone hydrochloride, and can dissolve the highly insoluble drug pioglitazone hydrochloride quickly without micronization.

[0013] Furthermore, the disintegrant is any one of cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, and low-substituted hydroxypropyl methylcellulose. By regulating the amount of disintegrant added, it is avoided that the disintegrant content is too high, which leads to reduced drug stability, drug degradation, ineffectiveness or deterioration.

[0014] Furthermore, the lubricant is talc or stearic acid.

[0015] Furthermore, the glidant is colloidal silicon dioxide or magnesium stearate.

[0016] The present invention also provides a method for preparing the compound tablet, comprising the following steps:

[0017] The binder is dissolved in the granulation solvent, empagliflozin is added and stirred until completely dissolved, the filler, lubricant and oligomeric proanthocyanidins are added into the fluidized bed top spray granulation and then dried, and then pioglitazone, disintegrant and glidant are added, mixed and tableted to obtain the compound tablet.

[0018] The present invention also provides a method for preparing the compound tablet, comprising the following steps:

[0019] The binder is dissolved in the granulation solvent, empagliflozin is added and stirred until completely dissolved, pioglitazone, filler, lubricant and oligomeric proanthocyanidins are added into the fluidized bed top spray granulation and then dried, and then a disintegrant and a glidant are added, mixed and tableted to obtain the composite tablet.

[0020] The present invention also provides a method for preparing the compound tablet, comprising the following steps:

[0021] The binder is dissolved in the granulation solvent, empagliflozin and pioglitazone are added and stirred until completely dissolved, the filler, lubricant and oligomeric proanthocyanidins are added into the fluidized bed top spray granulation and then dried, and then the disintegrant and glidant are added, mixed and tableted to obtain the compound tablet.

[0022] Furthermore, the granulation solvent is purified water or ethanol.

[0023] Furthermore, the drying temperature after granulation is 50-70°C.

[0024] Furthermore, the tablet weight is 250 mg, 360 mg or 500 mg.

[0025] Furthermore, the hardness of the tablet is 90N-110N. By controlling the tableting pressure, a reasonable tablet hardness is obtained. With the help of a proper tablet core structure, the reasonable dissolution rate of the two active substances is adjusted to achieve the effect of rapid in vitro release.

[0026] The present invention also provides use of the pioglitazone and empagliflozin compound tablet in preparing a medicine for preventing and / or treating diabetes.

[0027] Furthermore, the diabetes is type II diabetes.

[0028] In summary, compared with the prior art, the present invention achieves the following technical effects:

[0029] 1. The present invention provides a compound preparation for treating diabetes, wherein pioglitazone and empagliflozin are compounded to form a single tablet, wherein empagliflozin can be used to treat symptomatic chronic heart failure, and compounding pioglitazone and empagliflozin can reduce the risk of congestive heart failure caused or aggravated by pioglitazone, and can also reduce kidney damage and improve the body's glucose and lipid metabolism disorders, and also has good effects in reducing body weight, lowering blood pressure, and improving cardiac function. The use of pioglitazone and empagliflozin compound preparations in the treatment of type 2 diabetes can effectively reduce the number of medications taken by patients, increase patient compliance, increase drug efficacy, and reduce toxic side effects.

[0030] 2. The compound tablet of the present invention has high drug dissolution rate, can maintain the stability of dissolution rate under high temperature and high humidity, is durable in storage, can inhibit the growth of microorganisms, and prevent the drug from being contaminated and degraded by microorganisms.

[0031] 3. The present invention provides three different preparation methods for pioglitazone and empagliflozin compound tablets, all of which can ensure rapid dissolution of the drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0033] Figure 1 The method for preparing the pioglitazone-empagliflozin compound tablets of Example 1 of the present invention;

[0034] Figure 2 The method for preparing the pioglitazone-empagliflozin compound tablets of Example 5 of the present invention;

[0035] Figure 3 The method for preparing the pioglitazone-empagliflozin compound tablets of Example 6 of the present invention;

[0036] Figure 4 is the dissolution rate (%) of pioglitazone in the pioglitazone-empagliflozin compound tablet of the present invention at different times;

[0037] Figure 5 The dissolution stability results (%) of the pioglitazone-empagliflozin compound tablets of the present invention under high temperature and high humidity conditions. DETAILED DESCRIPTION

[0038] In order to enable those skilled in the art to better understand the scheme of the present invention, the technical scheme in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only embodiments of a part of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work should fall within the scope of protection of the present invention.

[0039] The experimental methods used in the following examples are conventional methods unless otherwise specified. The materials and reagents used are all commercially available unless otherwise specified.

[0040] Oligomeric proanthocyanidins: 02125, Saien Biotechnology;

[0041] Pioglitazone hydrochloride standard reference substance: Jiangsu Hengrui Medicine Co., Ltd.;

[0042] Commercially available pioglitazone hydrochloride tablets 1: Hangzhou Sino-US Huadong Pharmaceutical Co., Ltd., national medicine standard H20060664;

[0043] Commercially available pioglitazone hydrochloride tablets 2: Odibe, national medicine standard number H20052682;

[0044] Pioglitazone hydrochloride standard reference substance: Yangxin Pharmaceutical, 709E;

[0045] Commercially available empagliflozin tablets 1: Sichuan Kelun Pharmaceutical Co., Ltd., national medicine approval number: H20203410;

[0046] Commercially available empagliflozin tablets 2: Boehringer Ingelheim Pharma GmbH & Co, national medicine approval number: J20171074.

[0047] Example 1

[0048] The pioglitazone-empagliflozin compound preparation of this embodiment comprises the following components in parts by weight:

[0049] 24 parts of pioglitazone hydrochloride, 10 parts of empagliflozin, 4 parts of oligomeric proanthocyanidins, 146 parts of microcrystalline cellulose, 20 parts of povidone, 10 parts of cross-linked sodium carboxymethyl cellulose, 1 part of talc, and 1 part of colloidal silicon dioxide.

[0050] Preparation method:

[0051] Step 1: Pioglitazone hydrochloride was crushed and sieved, and the D50 particle size was measured to be 34 μm, and the D90 particle size was 152 μm; empagliflozin was crushed and sieved, and the D50 particle size was measured to be 9.22 μm, and the D90 particle size was 31.22 μm.

[0052] Step 2: Weigh povidone PVPK30 and dissolve it in ethanol solution, control the concentration of PVPK30 to be 10% (m / v), add empagliflozin after the solution becomes clear and transparent, stir until empagliflozin is completely dissolved, add oligomeric proanthocyanidins, microcrystalline cellulose and talc into a fluidized bed, use fluidized bed top spray granulation, sieve under a 1 mm sieve, dry at 50°C after granulation, add pioglitazone hydrochloride, cross-linked sodium carboxymethyl cellulose and colloidal silicon dioxide after granulation, mix and tablet, wherein the tablet weight is 250 mg, the tablet hardness is 90 N, and the preparation method is as follows: Figure 1 shown.

[0053] Example 2

[0054] The pioglitazone-empagliflozin compound preparation of this embodiment comprises the following components in parts by weight:

[0055] 36 parts of pioglitazone hydrochloride, 10 parts of empagliflozin, 6 parts of oligomeric proanthocyanidins, 310.56 parts of lactose, 20 parts of hypromellose, 16 parts of sodium carboxymethyl starch, 3 parts of stearic acid, and 2 parts of magnesium stearate.

[0056] Preparation method:

[0057] Step 1: Pioglitazone hydrochloride was crushed and sieved, and the D50 particle size was measured to be 34 μm, and the D90 particle size was 152 μm; empagliflozin was crushed and sieved, and the D50 particle size was measured to be 9.22 μm, and the D90 particle size was 31.22 μm.

[0058] Step 2: Weigh hydroxypropyl methylcellulose and dissolve it in ethanol solution. Control the concentration of hydroxypropyl methylcellulose to 20% (m / v). After the solution becomes clear and transparent, add empagliflozin and stir until empagliflozin is completely dissolved. Add oligomeric proanthocyanidins, lactose and stearic acid into the fluidized bed. Use fluidized bed top spray granulation and sieve with a 2 mm sieve. After granulation, dry at 60°C, add pioglitazone hydrochloride, sodium carboxymethyl starch and magnesium stearate to the granules, mix and compress the tablets. The tablet weight is 500 mg and the tablet hardness is 110 N.

[0059] Example 3

[0060] The pioglitazone-empagliflozin compound preparation of this embodiment comprises the following components in parts by weight:

[0061] 24 parts of pioglitazone hydrochloride, 5 parts of empagliflozin, 4 parts of oligomeric proanthocyanidins, 146 parts of microcrystalline cellulose, 10 parts of povidone, 10 parts of cross-linked sodium carboxymethyl cellulose, 1 part of talc, and 1 part of colloidal silicon dioxide.

[0062] Preparation method:

[0063] Step 1: Pioglitazone hydrochloride was crushed and sieved, and the D50 particle size was measured to be 34 μm, and the D90 particle size was 152 μm; empagliflozin was crushed and sieved, and the D50 particle size was measured to be 9.22 μm, and the D90 particle size was 31.22 μm.

[0064] Step 2: Weigh povidone PVPK30 and dissolve it in ethanol solution. Control the concentration of PVPK30 to be 10% (m / v). After the solution becomes clear and transparent, add empagliflozin and stir until empagliflozin is completely dissolved. Add oligomeric proanthocyanidins, microcrystalline cellulose and talc into the fluidized bed. Use fluidized bed top spray granulation and sieve with a 1 mm sieve. After granulation, dry at 70°C, add pioglitazone hydrochloride, cross-linked sodium carboxymethyl cellulose and colloidal silicon dioxide to mix and tablet. The tablet weight is 360 mg and the hardness of the tablet is 100 N.

[0065] Example 4

[0066] The pioglitazone-empagliflozin compound preparation of this embodiment comprises the following components in parts by weight:

[0067] 24 parts of pioglitazone hydrochloride, 5 parts of empagliflozin, 4 parts of oligomeric proanthocyanidins, 146 parts of microcrystalline cellulose, 20 parts of povidone, 10 parts of cross-linked sodium carboxymethyl cellulose, 1 part of talc, and 1 part of colloidal silicon dioxide.

[0068] Preparation method:

[0069] Step 1: Pioglitazone hydrochloride was crushed and sieved, and the D50 particle size was measured to be 34 μm, and the D90 particle size was 152 μm; empagliflozin was crushed and sieved, and the D50 particle size was measured to be 9.22 μm, and the D90 particle size was 31.22 μm.

[0070] Step 2: Weigh povidone PVPK30 and dissolve it in ethanol solution. Control the concentration of PVPK30 to be 10% (m / v). After the solution becomes clear and transparent, add empagliflozin and stir until empagliflozin is completely dissolved. Add oligomeric proanthocyanidins, microcrystalline cellulose and talc into the fluidized bed. Use fluidized bed top spray granulation and sieve with a 1 mm sieve. After granulation, dry at 50°C, add pioglitazone hydrochloride, cross-linked sodium carboxymethyl cellulose and colloidal silicon dioxide to mix and tablet. The tablet weight is 250 mg and the tablet hardness is 90 N.

[0071] Example 5

[0072] The pioglitazone-empagliflozin compound preparation of this embodiment comprises the following components in parts by weight:

[0073] 24 parts of pioglitazone hydrochloride, 10 parts of empagliflozin, 4 parts of oligomeric proanthocyanidins, 146 parts of microcrystalline cellulose, 20 parts of povidone, 10 parts of cross-linked sodium carboxymethyl cellulose, 1 part of talc, and 1 part of colloidal silicon dioxide.

[0074] Preparation method:

[0075] Step 1: Pioglitazone hydrochloride was crushed and sieved, and the D50 particle size was measured to be 34 μm, and the D90 particle size was 152 μm; empagliflozin was crushed and sieved, and the D50 particle size was measured to be 9.22 μm, and the D90 particle size was 31.22 μm.

[0076] Step 2: dissolve povidone PVPK30 in ethanol solution, control the concentration of PVPK30 to be 10% (m / v), add empagliflozin and pioglitazone hydrochloride after the solution becomes clear, add oligomeric proanthocyanidins, microcrystalline cellulose and talc into a fluidized bed, use fluidized bed top spray granulation, dry at 50°C after granulation, add cross-linked sodium carboxymethyl cellulose and colloidal silicon dioxide after granulation, mix and tablet, wherein the tablet weight is 250 mg, the tablet hardness is 90 N, and the preparation method is as follows: Figure 2 shown.

[0077] Example 6

[0078] The pioglitazone-empagliflozin compound preparation of this embodiment comprises the following components in parts by weight:

[0079] 24 parts of pioglitazone hydrochloride, 10 parts of empagliflozin, 4 parts of oligomeric proanthocyanidins, 146 parts of microcrystalline cellulose, 20 parts of povidone, 10 parts of cross-linked sodium carboxymethyl cellulose, 1 part of talc, and 1 part of colloidal silicon dioxide.

[0080] Preparation method:

[0081] Step 1: Pioglitazone hydrochloride was crushed and sieved, and the D50 particle size was measured to be 34 μm, and the D90 particle size was 152 μm; empagliflozin was crushed and sieved, and the D50 particle size was measured to be 9.22 μm, and the D90 particle size was 31.22 μm.

[0082] Step 2: dissolve povidone PVPK30 in ethanol solution, control the concentration of PVPK30 to be 10% (m / v), add empagliflozin and pioglitazone hydrochloride after the solution becomes clear, add oligomeric proanthocyanidins, microcrystalline cellulose and talc into a fluidized bed, use fluidized bed top spray granulation, dry at 50°C after granulation, add cross-linked sodium carboxymethyl cellulose and colloidal silicon dioxide after granulation, mix and tablet, wherein the tablet weight is 250 mg, the tablet hardness is 90 N, and the preparation method is as follows: Figure 3 shown.

[0083] Comparative Example 1

[0084] The pioglitazone-empagliflozin compound preparation of this embodiment comprises the following components in parts by weight:

[0085] 24 parts of pioglitazone hydrochloride, 10 parts of empagliflozin, 4 parts of oligomeric proanthocyanidins, 146 parts of microcrystalline cellulose, 10 parts of povidone, 10 parts of cross-linked sodium carboxymethyl cellulose, 1 part of talc, and 1 part of colloidal silicon dioxide.

[0086] Preparation method:

[0087] Step 1: Pioglitazone hydrochloride was crushed and sieved, and the D50 particle size was measured to be 34 μm, and the D90 particle size was 152 μm; empagliflozin was crushed and sieved, and the D50 particle size was measured to be 9.22 μm, and the D90 particle size was 31.22 μm.

[0088] Step 2: Weigh povidone PVPK30 and dissolve it in ethanol solution. Control the concentration of PVPK30 to be 10% (m / v). After the solution becomes clear and transparent, add empagliflozin and stir until empagliflozin is completely dissolved. Add oligomeric proanthocyanidins, microcrystalline cellulose and talc into the fluidized bed. Use fluidized bed top spray granulation and sieve with a 1 mm sieve. After granulation, dry at 50°C, add pioglitazone hydrochloride, cross-linked sodium carboxymethyl cellulose and colloidal silicon dioxide to mix and tablet. The tablet weight is 250 mg and the tablet hardness is 90 N.

[0089] Comparative Example 2

[0090] The pioglitazone-empagliflozin compound preparation of this embodiment comprises the following components in parts by weight:

[0091] 24 parts of pioglitazone hydrochloride, 10 parts of empagliflozin, 146 parts of microcrystalline cellulose, 20 parts of povidone, 10 parts of cross-linked carboxymethyl cellulose sodium, 1 part of talc, and 1 part of colloidal silicon dioxide.

[0092] Preparation method:

[0093] Step 1: Pioglitazone hydrochloride was crushed and sieved, and the D50 particle size was measured to be 60 μm, and the D90 particle size was 200 μm; empagliflozin was crushed and sieved, and the D50 particle size was measured to be 20 μm, and the D90 particle size was 40 μm.

[0094] Step 2: Weigh povidone PVPK30 and dissolve it in ethanol solution. Control the concentration of PVPK30 to be 10% (m / v). After the solution becomes clear and transparent, add empagliflozin and stir until empagliflozin is completely dissolved. Add microcrystalline cellulose and talc into the fluidized bed and use fluidized bed top spray granulation. Sieve under a 1 mm sieve. After granulation, dry at 50°C, add pioglitazone hydrochloride, cross-linked sodium carboxymethyl cellulose and colloidal silicon dioxide to mix and compress the tablets. The tablet weight is 250 mg and the tablet hardness is 90 N.

[0095] Comparative Example 3

[0096] The pioglitazone-empagliflozin compound preparation of this embodiment comprises the following components in parts by weight:

[0097] 24 parts of pioglitazone hydrochloride, 10 parts of empagliflozin, 4 parts of oligomeric proanthocyanidins, 146 parts of microcrystalline cellulose, 30 parts of povidone, 10 parts of cross-linked sodium carboxymethyl cellulose, 1 part of talc, and 1 part of colloidal silicon dioxide.

[0098] Preparation method:

[0099] Step 1: Pioglitazone hydrochloride was crushed and sieved, and the D50 particle size was measured to be 34 μm, and the D90 particle size was 152 μm; empagliflozin was crushed and sieved, and the D50 particle size was measured to be 9.22 μm, and the D90 particle size was 31.22 μm.

[0100] Step 2: Weigh povidone PVPK30 and dissolve it in ethanol solution. Control the concentration of PVPK30 to be 10% (m / v). After the solution becomes clear and transparent, add empagliflozin and stir until empagliflozin is completely dissolved. Add oligomeric proanthocyanidins, microcrystalline cellulose and talc into the fluidized bed. Use fluidized bed top spray granulation and sieve with a 1 mm sieve. After granulation, dry at 50°C, add pioglitazone hydrochloride, cross-linked sodium carboxymethyl cellulose and colloidal silicon dioxide to mix and tablet. The tablet weight is 250 mg and the tablet hardness is 90 N.

[0101] Comparative Example 4

[0102] The pioglitazone-empagliflozin compound preparation of this embodiment comprises the following components in parts by weight:

[0103] 24 parts of pioglitazone hydrochloride, 10 parts of empagliflozin, 4 parts of oligomeric proanthocyanidins, 146 parts of microcrystalline cellulose, 20 parts of povidone, 25 parts of cross-linked sodium carboxymethyl cellulose, 1 part of talc, and 1 part of colloidal silicon dioxide.

[0104] Preparation method:

[0105] Step 1: Pioglitazone hydrochloride was crushed and sieved, and the D50 particle size was measured to be 34 μm, and the D90 particle size was 152 μm; empagliflozin was crushed and sieved, and the D50 particle size was measured to be 9.22 μm, and the D90 particle size was 31.22 μm.

[0106] Step 2: Weigh povidone PVPK30 and dissolve it in ethanol solution. Control the concentration of PVPK30 to be 10% (m / v). After the solution becomes clear and transparent, add empagliflozin and stir until empagliflozin is completely dissolved. Add oligomeric proanthocyanidins, microcrystalline cellulose and talc into the fluidized bed. Use fluidized bed top spray granulation and sieve with a 1 mm sieve. After granulation, dry at 50°C, add pioglitazone hydrochloride, cross-linked sodium carboxymethyl cellulose and colloidal silicon dioxide to mix and tablet. The tablet weight is 250 mg and the tablet hardness is 90 N.

[0107] Comparative Example 5

[0108] The pioglitazone-empagliflozin compound preparation of this embodiment comprises the following components in parts by weight:

[0109] 24 parts of pioglitazone hydrochloride, 10 parts of empagliflozin, 10 parts of oligomeric proanthocyanidins, 146 parts of microcrystalline cellulose, 20 parts of povidone, 10 parts of cross-linked sodium carboxymethyl cellulose, 1 part of talc, and 1 part of colloidal silicon dioxide.

[0110] Preparation method:

[0111] Step 1: Pioglitazone hydrochloride was crushed and sieved, and the D50 particle size was measured to be 34 μm, and the D90 particle size was 152 μm; empagliflozin was crushed and sieved, and the D50 particle size was measured to be 9.22 μm, and the D90 particle size was 31.22 μm.

[0112] Step 2: Weigh povidone PVPK30 and dissolve it in ethanol solution. Control the concentration of PVPK30 to be 10% (m / v). After the solution becomes clear and transparent, add empagliflozin and stir until empagliflozin is completely dissolved. Add oligomeric proanthocyanidins, microcrystalline cellulose and talc into the fluidized bed. Use fluidized bed top spray granulation and sieve with a 1 mm sieve. After granulation, dry at 50°C, add pioglitazone hydrochloride, cross-linked sodium carboxymethyl cellulose and colloidal silicon dioxide to mix and tablet. The tablet weight is 250 mg and the tablet hardness is 90 N.

[0113] 1. Dissolution and dissolution stability test:

[0114] Since pioglitazone hydrochloride is insoluble in water and phosphate buffer (pH 6.8), but dissolves in 0.1 mol / L hydrochloric acid solution, 0.1 mol / L hydrochloric acid is selected as the dissolution medium. The pioglitazone-empagliflozin compound tablets prepared in Examples 1 to 6 and Comparative Examples 1 to 5 were compared with pioglitazone hydrochloride tablets from two different manufacturers and empagliflozin tablets from two different manufacturers, and the dissolution at 5, 10, 15, 20, 30, and 45 min, respectively, and the dissolution stability after 3 months and 6 months of storage under high temperature and high humidity (40°C, relative humidity RH75%) conditions were investigated.

[0115] (1) Experimental instruments and models: Agilent Technologies, Agilent 1260 Infinity II HPLC system.

[0116] (2) Dissolution conditions: According to the dissolution conditions given on the website of the U.S. Food and Drug Administration (FDA), the paddle method was used, with a paddle speed of 100 rpm for pioglitazone and 900 mL of 0.01N HCl solution as the dissolution medium. The dissolution medium for empagliflozin was 900 mL of pH 6.8 phosphate buffer and a paddle speed of 75 rpm.

[0117] (3) Chromatographic conditions:

[0118] Chromatographic conditions for pioglitazone detection: C18 column, 150 mm × 4.6 mm, particle size 5 µm. 0.1% phosphoric acid aqueous solution-acetonitrile (30:70) as mobile phase; detection wavelength at 270 nm; column temperature at 30°C; samples were filtered using a 0.45 μm filter membrane.

[0119] Chromatographic conditions for empagliflozin detection: C18 column, 150 mm × 4.6 mm, particle size 5 µm. Water-acetonitrile-trifluoroacetic acid (70:30:0.05), detection wavelength 270 nm; samples were filtered using a 0.45 μm filter membrane.

[0120] (4) The test results are shown in Tables 1 to 3 and Figures 4 and 5 shown.

[0121] Table 1 Dissolution of pioglitazone in pioglitazone-empagliflozin compound tablets at different times (%)

[0122]

[0123] Table 2 Dissolution of empagliflozin in pioglitazone-empagliflozin compound tablets at different times (%)

[0124]

[0125] Table 3 Dissolution stability results of pioglitazone-empagliflozin compound tablets under high temperature and high humidity (%)

[0126]

[0127] As can be seen from the data in Tables 1 to 2, under the above dissolution conditions, it can be seen from the dissolution behavior of commercially available pioglitazone hydrochloride tablets and empagliflozin tablets that the initial dissolution of pioglitazone hydrochloride tablets and empagliflozin tablets prepared by different manufacturers is different. The peak time in the dissolution curve of the embodiment is the same, the onset sequence, and there is no significant difference in dissolution. The same bioavailability can be achieved when acting in vivo, while the peak time in the comparative example is relatively later, and the onset in vivo is relatively slow, forming different slopes, and having different bioavailabilities in vivo. In Comparative Example 1, the ratio of binder to empagliflozin is 1:1. Due to the high viscosity of povidone, the prepared particles are easy to agglomerate, which reduces the dissolution rate of empagliflozin. In Comparative Example 2, no oligomeric proanthocyanidins were added, and the solubility of pioglitazone and empagliflozin decreased. In Comparative Examples 3 and 4, excessive additives (excessive binder in Comparative Example 3 and excessive disintegrant in Comparative Example 4) affected the drug solubility. In Comparative Example 5, excessive oligomeric proanthocyanidins were also not conducive to the rapid dissolution of pioglitazone and empagliflozin.

[0128] The results in Table 3 show that the particle size of the drug in the compound tablets and the type and amount of additives have different degrees of influence on the dissolution stability of the tablets. In Comparative Example 1, the compounding ratio of the binder and empagliflozin is outside the range of (2-4):1, and the dissolution rate decreases after long-term storage; in Comparative Example 2, no oligomeric proanthocyanidins are added, and the initial dissolution rate of the compound tablets is low; in Comparative Example 3, the binder is excessive, and in Comparative Example 4, the disintegrant is excessive, which also affects the dissolution stability of the drug; in Comparative Example 5, the excessive oligomeric proanthocyanidins can significantly affect the dissolution stability of pioglitazone hydrochloride. After the oligomeric proanthocyanidins are compounded with pioglitazone and empagliflozin, the decline in dissolution rate is significantly reduced, thereby improving the stability and absorption rate of the drug in the body and ensuring the effectiveness of the medication.

[0129] 2. Determination of related substances and impurities:

[0130] The compound tablets obtained in Examples 1 to 6 and Comparative Examples 1 to 5 were stored in an open state at 40°C / 75%RH for 3 months, and the total analog content (i.e., total impurity content) was determined by high performance liquid chromatography. The total analog mass refers to the sum of the analog mass calculated based on the area of ​​the effective ingredient from the peaks other than pioglitazone, empagliflozin and additives as the analog peaks, and the results are shown in Table 4:

[0131] Table 4 Determination results of total analogue content in each example and comparative example

[0132]

[0133] The results in Table 4 show that the total impurity content of the compound tablets prepared in the examples increases slowly after storage for 3 months, and the total impurity content of the compound tablets prepared by the method of Example 1 is the lowest after storage for 3 months. In the comparative example, oligomeric proanthocyanidins and binders can significantly affect the stability of the compound tablets. Oligomeric proanthocyanidins have certain antibacterial properties, which can inhibit the growth of microorganisms in the preparation, prevent the drug from being contaminated and degraded by microorganisms, and produce synergistic effects with pioglitazone and empagliflozin in the compound tablets to improve the stability of the drug.

[0134] 3. Effects of different compound tablets on blood glucose in normal mice.

[0135] The compound tablets of Examples 1 to 4 were selected as combinations 1 to 4, and the dosage was 250 mg / day.

[0136] Twenty-five Wistar male rats weighing about 250 g were selected and randomly divided into five groups after one week of adaptive feeding, with five rats in each group. They were fed with a high-fat diet. The high-fat diet was prepared with protein, fat, and carbohydrates of 13.5, 37.5, and 41.9 (%, w / w), respectively. After nine weeks of high-fat diet feeding, four groups began to be given the same dosage as in combination one to four, and the fifth group was not given the same dosage, which served as the blank control. The administration continued for 20 days, and the rats were fasted on the 21st day. The next day, the tail was cut off and blood was collected to measure fasting blood glucose. Blood was collected from the orbital venous plexus at 30 min, 60 min, and 120 min after conventional administration and glucose load (2 g / kg, ig), and the blood glucose level was measured using the PrecisionQ*I*D blood glucose meter from Abbott, USA.

[0137] The area under the glucose tolerance curve (AUC) = 0.5 × fasting blood sugar + 30 min blood sugar + 1.5 × 60 min blood sugar + 120 min blood sugar. A low AUC value indicates that blood sugar rises rapidly in a short period of time and returns to normal levels, indicating that the body has good insulin sensitivity and glucose tolerance. A high AUC value indicates that blood sugar remains at a high level for a long time, reflecting insulin resistance or insufficient insulin secretion.

[0138] The results are shown in Table 5.

[0139] Table 5 Changes of glucose content and area under the glucose tolerance curve in rats of each group

[0140]

[0141] Compared with the normal control group,* P <0.05,** P <0.01,n=5.

[0142] No mice died in the experiment. As shown in Table 5, compared with the blank group, each combination had a significant inhibitory effect on the increase of postprandial blood glucose in normal rats, and compared with the area under the glucose tolerance curve of the blank control, each combination could alleviate the impaired glucose tolerance of rats after medication. The compound tablets of the present invention can effectively reduce the fluctuation range of blood glucose and have no adverse reactions such as heart failure.

[0143] In summary, the present invention provides a compound preparation of pioglitazone and empagliflozin. By optimizing the particle size of each raw material in the compound preparation, the type and content of additives, and different preparation methods, oligomeric proanthocyanidins are additionally added to the preparation to ensure the rapid dissolution effect of the compound preparation, and improve the dissolution stability of the compound preparation after storage under high temperature and high humidity, and the dissolution decline is significantly reduced. The compound preparation of the present invention can improve the stability of the drug, inhibit the growth of microorganisms, and ensure the effectiveness of medication. The present invention compounds pioglitazone and empagliflozin to effectively reduce the fluctuation range of blood sugar. Empagliflozin reduces blood sugar by inhibiting the reabsorption of glucose by the kidneys, thereby reducing kidney damage in the body, and improving the body's glucose and lipid metabolism disorders. It also has good effects in reducing body weight, lowering blood pressure, and improving cardiac function.

[0144] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A pioglitazone and empagliflozin compound tablet, It is characterized in that In parts by weight, it includes the following components: Pioglitazone 24-36 parts; Empagliflozin 5-10 parts; 4-6 parts of oligomeric proanthocyanidins; Filler 146~315 parts; 10~20 parts of adhesive; 10-16 parts of disintegrant; 1~3 parts of lubricant; 1~2 parts of flow aid; Among them, the mass ratio of the binder to empagliflozin is (2-4):1; The filler is any one of microcrystalline cellulose, lactose, and pregelatinized starch; The binder is any one of hypromellose and povidone; The disintegrant is any one of cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, and low-substituted hydroxypropyl methylcellulose; The glidant is colloidal silicon dioxide or magnesium stearate; The preparation method of the pioglitazone and empagliflozin compound tablet is any one of the following: (1) dissolving the binder in the granulation solvent, adding empagliflozin and stirring until completely dissolved, adding the filler, lubricant, and oligomeric proanthocyanidins into the fluidized bed top spray granulation and drying, and then adding pioglitazone, disintegrant, and glidant, mixing, and tableting to obtain the composite tablet; (2) dissolving the binder in the granulation solvent, adding empagliflozin and stirring until completely dissolved, adding pioglitazone, filler, lubricant, and oligomeric proanthocyanidins into the fluidized bed top spray granulation, and drying, and then adding disintegrant and glidant, mixing, and tableting to obtain the composite tablet; (3) The binder is dissolved in the granulation solvent, and empagliflozin and pioglitazone are added and stirred until completely dissolved. The filler, lubricant, and oligomeric proanthocyanidins are added to the fluidized bed top spray granulation and then dried. Disintegrants and glidants are then added, mixed, and tableted to obtain the composite tablets.

2. The pioglitazone and empagliflozin compound tablet according to claim 1, It is characterized in that The D50 particle size of the pioglitazone is 20-40 μm; the D50 particle size of the empagliflozin is 5-15 μm.

3. Use of the pioglitazone and empagliflozin compound tablet according to any one of claims 1 to 2 in the preparation of a medicament for treating diabetes.